IMPARP: Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation

• Sponsor: Ying Lin (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT05761470
• Collaborator: (none)
• Enrollment: 66
• Location: 1
• Arm: 1
• Anticipated Duration (Months): 79.9
• Patients Per Site Per Month: 0.8

Study Details

Study Description

Brief Summary

This study is to evaluate the efficacy and safety of combination of Camrelizumab (Immunotherapy, PD-1 inhibitor), Fluzoparib (PARP inhibitor) and Nab-paclitaxel in neoadjuvant therapy of Her-2 negative breast cancer patients with HRR gene mutation.

Condition or Disease	Intervention/Treatment	Phase
Her-2 Negative Breast Cancer; HRR Gene Mutation	Drug: Camrelizumab; Drug: Fluzoparib; Drug: Nab-paclitaxel	Phase 2

Detailed Description

This is a prospective, single-center, open-label phase II clinical trial investigating the activity of Camrelizumab+Fluzoparib+Nab-paclitaxel combination therapy in breast cancer patients with Her2-negative and HRR gene mutation for neoadjuvant therapy.

Anticipated 66 candidates meeting all study eligibility criteria will receive 8 cycles of Nab-paclitaxel (260mg/m2) every 3 weeks, which will add Camrelizumab (200mg, d1) and Fluzoparib (100mg BID) from the second cycle.

HRR gene mutation contains at least one pathogenic or likely pathogenic variant in germline or somatic BRCA1, BCRA2 and PALB2 genes, or in germline ATM, BARD1, BRIP1, CDK12, CHEK2, RAD51C, RAD51D genes.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 66 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Study of Camrelizumab, Fluzoparib and Nab-paclitaxel in Neoadjuvant Therapy of Her-2 Negative Breast Cancer Patients With HRR Gene Mutation
• Actual Study Start Date: May 6, 2022
• Anticipated Primary Completion Date: Jun 30, 2024
• Anticipated Study Completion Date: Dec 31, 2028

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Camrelizumab, Fluzoparib and Nab-paclitaxel Participants who confirmed pathogenic or likely pathogenic HRR gene mutation received Camrelizumab and Fluzoparib with nab-paclitaxel from the second cycle followed by nab-paclitaxel for one cycle.	Drug: Camrelizumab; Camrelizumab at a fixed dose of 200mg via IV infusion on Days 1 each 21-day cycle. Fluzoparibat at a fixed dose of 100mg BID, each 21-day cycle. Nab-paclitaxel at a fixed dose of 260 milligrams via intravenous (IV) infusion on Days 1 each 21-day cycle.; Drug: Fluzoparib; Fluzoparib; Drug: Nab-paclitaxel; Nab-paclitaxel

Outcome Measures

Primary Outcome Measures

1. Pathologic Complete Response (pCR) [Up to 32 weeks]

   Pathologic response will be assessed in the surgically resected cancer and lymph nodes after completion of all chemotherapy by the local pathologist as part of routine care. Pathologic complete response is defined as no invasive cancer in the resected breast tissue and lymph nodes (ypT0/Tis, ypN0).

Secondary Outcome Measures

1. Objective Response Rate (ORR) [Up to 32 weeks]

   ORR is defined as percentage of participants with Complete Response and Partial Response

2. Residual Cancer Burden (RCB) [Up to 32 weeks]

   Pathologilly assessed residual cancer burden according to MD Anderson protocol.

3. Event-Free Survival (EFS) [Up to 20 years]

   EFS was defined as the time from the date of randomization to the date of events from any cause.

4. Overall Survival (OS) [Up to 20 years]

   OS was defined as the time from the date of randomization to the date of death from any cause.

5. Safety of drugs [Up to 32 weeks]

   Adverse effects of the candidates according to NCI-CTCAE 5.0

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 75 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Histologically documented Her-2 negative

• TNM stage: T1c, N1-N2；T2-4, N0-N2；any T, N3

• No distant metastatic disease

• Eastern Cooperative Oncology Group Performance Status: 0~1

• HRR gene mutation: at least one pathogenic or likely pathogenic variant in germline or somatic BRCA1, BCRA2 and PALB2 genes, or in germline ATM, BARD1, BRIP1, CDK12, CHEK2, RAD51C, RAD51D genes.

Exclusion Criteria:

• Patients who are pregnant or lactating at the time of randomization or refuse to contraception.

• Patients who have other malignant diseases within 2 years, except for cured skin basal cell carcinoma, breast carcinoma in situ or cervical carcinoma in situ

• Patients with psychiatric disorder, peripheral or central nerve system disease or any disorder, which compromises ability to give informed consent or participate in this study.

• Patients who have myocardial infarction or congestive heart failure, or other serious cardiac disease.

• Patients who have used immunosuppressive drug or corticosteroids within 14 days.

• Patients who have other diseases which researchers.

• Patients who allergy to any of the drugs in this trail.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	First Affiliated Hospital, Sun Yat-Sen University	Guangzhou	Guangdong	China	510080

Sponsors and Collaborators

• Ying Lin

Investigators

• Study Chair: Ying Lin, MD, Principal Investigator

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Ying Lin, director of department, First Affiliated Hospital, Sun Yat-Sen University
• ClinicalTrials.gov Identifier: NCT05761470
• Other Study ID Numbers: 20220430GD
• First Posted: Mar 9, 2023
• Last Update Posted: Mar 9, 2023
• Last Verified: Mar 1, 2023

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Breast Neoplasms; Paclitaxel

Study Results

No Results Posted as of Mar 9, 2023